About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT

Company recently progressed DIAG723 into IND-enabling studies for HHT and pulmonary arterial hypertension (PAH)

WATERTOWN, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with multispecific antibodies that address the underlying cause of intractable genetic diseases, today announced the initiation of a natural history study for hereditary hemorrhagic telangiectasia (HHT) in partnership with patient advocacy group Cure HHT. This first-of-its-kind non-interventional, observational, longitudinal evaluation aims to characterize the variability of patient-reported outcomes, including epistaxis (nosebleeds), hematologic support, and quality of life (QoL).

“Our ongoing collaboration with Cure HHT has been instrumental in building strong connections with the HHT community, and we express our heartfelt gratitude to the many individuals living with HHT who volunteered to participate in this critical study,” said Alex Lugovskoy, Ph.D., Chief Executive Officer of Diagonal. “This study is designed to capture daily changes and adjustments in behavior related to the extensive symptom burden associated with the disease, while informing efficient trial design to accelerate the development of novel treatments.”

HHT is an autosomal dominant genetic disorder in which abnormal blood vessel formation leads to bleeding that can be serious or life-threatening. The prevalence of HHT has been estimated at 1.5 to 2 per 10,000 people or approximately 1.4 million people worldwide1. There are currently no approved drugs that target the disease. Current treatments used to address the disease manifestations include off-label drugs previously approved for cancer indications.

“Given the lack of approved therapies, we are excited to expand our partnership with Diagonal on their natural history study and believe it will play a pivotal role in advancing a validated body of knowledge surrounding HHT’s natural history, progression and variability across affected adults,” said Marianne Clancy, MPA, Executive Director of Cure HHT. “By prioritizing studies that illuminate the full scope and impact of HHT, we ignite a new era of discovery to accelerate the development of breakthrough treatments that directly target disease-driving biology, bringing renewed hope for individuals and families seeking life-changing solutions.”

Diagonal recently presented a health economic and outcomes research (HEOR) analysis focused on the cost and clinical burden in people living with HHT at the 2024 American Society of Hematology (ASH) annual meeting, with results demonstrating that the healthcare costs associated with HHT have been significantly underestimated.

The prospective natural history study is ongoing and aims to enroll more than 100 adults in the U.S. with a confirmed diagnosis of HHT. Throughout the 13-month evaluation period, subjects will record healthcare utilization, hematologic support, daily epistaxis scores, and other periodic (electronic) patient-reported outcomes (ePROS) on a study-specific mobile application developed by Diagonal. Subjects will participate in regular check-ins with study staff via telehealth.

In addition to providing important insights into the disease, the analysis of primary and secondary study outcomes will help to inform the design of future randomized clinical trials and FDA interactions. Diagonal recently progressed DIAG723, a bispecific agonist antibody designed to restore normal biological signaling in people living with HHT, into IND-enabling studies. DIAG723 is also being developed for people living with PAH.

References
1. Grosse, S., Boulet, S., Grant, A. et al. The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia. Genet Med 16, 33–39 (2014). https://doi.org/10.1038/gim.2013.66

About Hereditary Hemorrhagic Telangiectasia (HHT) 
HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss of function point mutations in members of the TGF-β receptor superfamily complex create abnormal blood vessels that are fragile and susceptible to rupture and bleeding. These bleeding events lead to chronic anemia, necessitating frequent iron infusions or red blood cell transfusions. Internal arteriovenous malformations, if left untreated, are at risk of rupturing, resulting in lung and brain hemorrhage, stroke, heart failure, and death.

About DIAG723
DIAG723 is a bispecific antibody designed to address HHT and PAH, in which dysregulated ALK1 signaling at the endothelium drives the formation of fragile arteriovenous malformations or vascular hyperproliferation, respectively. DIAG723 restores signaling lost due to mutations that impair receptor function. In multiple HHT preclinical studies, DIAG723 prevented and reversed arteriovenous malformations – a hallmark of HHT that can cause a host of bleeding-related complications in various organs. In addition, DIAG723 was found to restore signaling in multiple HHT patient donor samples. In preclinical models of PAH, DIAG723 prevented disease development and cardiac remodeling, and improved hemodynamics. DIAG723 also restored normal signaling in pulmonary microvascular endothelial cells derived from multiple PAH donors.

About Diagonal Therapeutics
Diagonal Therapeutics is a biotech company advancing novel disease-modifying antibodies that repair aberrant signaling implicated in a range of illnesses. The Company's DIAGONAL Product Engine combines proprietary computational and experimental techniques to overcome historical challenges associated with antibody drug discovery and efficiently deliver optimized therapeutic assets. Diagonal's emerging pipeline comprises multispecific biologics designed to selectively address the underlying cause of disease, offering the potential to deliver life-changing therapies for patients. For more information, please visit www.diagonaltx.com.

Media Contact
Peg Rusconi
media@diagonaltx.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.